Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDA
May 21, 2015 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, May 21, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports Director Election Results
April 22, 2015 13:35 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 22, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces First Quarter 2015 Results
April 14, 2015 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, April 14, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports Positive Topline Data Results from a Series of Phase I Clinical Trials of its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, and files an IND for Rexista(TM) Oxycodone XR
March 30, 2015 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, March 30, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces 2014 Year End Results With a 48% Reduction in Operating Loss
February 23, 2015 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Reports the Signing of an Exclusive Licensing and Manufacturing Agreement With Teva Pharmaceuticals USA, Inc. for an Extended Release Oral Drug Product Candidate
February 02, 2015 08:00 ET
|
Intellipharmaceutics International Inc.
TORONTO, Feb. 2, 2015 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Notes Launch of 5mg Strength of Focalin XR(R) Generic by Teva
November 20, 2014 07:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the...
Intellipharmaceutics Announces Appointment of New Chief Financial Officer
November 18, 2014 07:30 ET
|
Intellipharmaceutics International Inc.
TORONTO, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of...
Intellipharmaceutics Reports That the FDA Has Given Its Toronto Manufacturing Facility an "Acceptable" Classification
October 27, 2014 07:15 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...
Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin(TM) XR (Pregabalin Extended-Release)
October 22, 2014 17:15 ET
|
Intellipharmaceutics International Inc.
TORONTO, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel...